Benefit-Risk Analysis: A Brief Review and Proposed Quantitative Approaches

By Holden W.L.  

Drug Safety, Vol. 26, Iss. 12, 2003-01 ,pp. : 853-862

Adis International

Access to resources Recommend Favorite

Using the Incremental Net Benefit Framework for Quantitative Benefit–Risk Analysis in Regulatory Decision-Making—A Case Study of Alosetron in Irritable Bowel Syndrome

By Lynd Larry D.   Najafzadeh Mehdi   Colley Lindsey   Byrne Michael F.   Willan Andrew R.   Sculpher Mark J.   Johnson F. Reed   Hauber A. Brett  

Value in Health, Vol. 13, Iss. 4, 2010-06 ,pp. : 411-417

Blackwell Publishing

Access to resources Recommend Favorite

Drug-Eluting Stents in Percutaneous Coronary Intervention: A Benefit-Risk Assessment

By Byrne Robert A.   Sarafoff Nikolaus   Kastrati Adnan   Schömig Albert  

Drug Safety, Vol. 32, Iss. 9, 2009-09 ,pp. : 749-770

Adis International

Access to resources Recommend Favorite

Evaluation of Benefit-Risk

By Garattini Silvio  

PharmacoEconomics, Vol. 28, Iss. 11, 2010-11 ,pp. : 981-986

Adis International

Access to resources Recommend Favorite

A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy—Report of the ISPOR Risk–Benefit Management Working Group

By Guo Jeff J.   Pandey Swapnil   Doyle John   Bian Boyang   Lis Yvonne   Raisch Dennis W.  

Value in Health, Vol. 13, Iss. 5, 2010-08 ,pp. : 657-666

Blackwell Publishing

Access to resources Recommend Favorite